As European markets experience a resurgence, with the pan-European STOXX Europe 600 Index climbing 3.93% over a recent week, investor sentiment has been buoyed by the European Central Bank's rate cuts and delayed tariff impositions. In this environment of renewed optimism, identifying undervalued stocks becomes crucial for investors seeking opportunities to capitalize on potential market corrections and economic shifts.
Name | Current Price | Fair Value (Est) | Discount (Est) |
Cenergy Holdings (ENXTBR:CENER) | €8.42 | €16.43 | 48.8% |
Mips (OM:MIPS) | SEK352.60 | SEK692.82 | 49.1% |
LPP (WSE:LPP) | PLN15610.00 | PLN30723.31 | 49.2% |
Lindab International (OM:LIAB) | SEK186.80 | SEK371.74 | 49.8% |
Verbio (XTRA:VBK) | €9.24 | €18.22 | 49.3% |
TF Bank (OM:TFBANK) | SEK345.50 | SEK669.05 | 48.4% |
Etteplan Oyj (HLSE:ETTE) | €11.55 | €23.07 | 49.9% |
Stille (OM:STIL) | SEK209.00 | SEK400.76 | 47.8% |
Komplett (OB:KOMPL) | NOK11.50 | NOK22.67 | 49.3% |
Fodelia Oyj (HLSE:FODELIA) | €7.14 | €13.91 | 48.7% |
Click here to see the full list of 179 stocks from our Undervalued European Stocks Based On Cash Flows screener.
Here we highlight a subset of our preferred stocks from the screener.
Overview: Exosens develops, manufactures, and sells electro-optical technologies for amplification, detection, and imaging across various regions including France, Europe, North America, Asia, Oceania, Africa and internationally; it has a market cap of €1.71 billion.
Operations: The company's revenue is primarily derived from its amplification segment, which generates €280.20 million, and its detection and imaging segment, contributing €117.50 million.
Estimated Discount To Fair Value: 41%
Exosens is trading at €33.6, significantly below its estimated fair value of €56.93, highlighting its undervaluation based on discounted cash flow analysis. Recent earnings showed substantial growth, with sales reaching €394.1 million and net income rising to €30.7 million in 2024. The company's strategic expansion into the U.S., coupled with increased demand for night vision products driven by defense needs, positions it well for future revenue growth despite a volatile share price recently.
Overview: Pluxee N.V. provides employee benefits and engagement solutions services across France, Latin America, Continental Europe, and internationally with a market capitalization of approximately €3.21 billion.
Operations: Revenue Segments (in millions of €): Employee Benefits: 2,500; Engagement Solutions: 1,200; International Services: 800.
Estimated Discount To Fair Value: 42.9%
Pluxee is trading at €21.98, substantially below its estimated fair value of €38.5, indicating significant undervaluation based on discounted cash flow analysis. Recent earnings results showed robust growth with net income rising to €97 million from €66 million a year ago. Despite being dropped from the FTSE All-World Index, Pluxee's share repurchase program and forecasted revenue growth of 8.6% annually suggest potential for improved financial performance in the future.
Overview: Ströer SE & Co. KGaA operates in the out-of-home and digital out-of-home advertising sectors both in Germany and internationally, with a market capitalization of approximately €2.85 billion.
Operations: Ströer SE & Co. KGaA generates revenue through its segments: Daas & E-Commerce (€357.79 million), Out-Of-Home Media (€953.21 million), and Digital & Dialog Media (€878.25 million).
Estimated Discount To Fair Value: 29.9%
Ströer SE & Co. KGaA, trading at €51, is significantly undervalued with an estimated fair value of €72.79 based on discounted cash flow analysis. The company reported a strong increase in net income to €147.5 million for 2024 from the previous year's €112.4 million, reflecting robust earnings growth of 40.9%. However, despite a high forecasted return on equity and earnings growth outpacing the German market, its dividend coverage remains weak amid substantial debt levels.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ENXTPA:EXENS ENXTPA:PLX and XTRA:SAX.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。